Deep Learning-Assisted interactive contouring of lung Cancer: Impact on contouring time and consistency.

Deep learning Interactive contouring Lung tumour NSCLC

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
03 Sep 2024
Historique:
received: 10 06 2023
revised: 24 07 2024
accepted: 19 08 2024
medline: 6 9 2024
pubmed: 6 9 2024
entrez: 5 9 2024
Statut: aheadofprint

Résumé

To evaluate the impact of a deep learning (DL)-assisted interactive contouring tool on inter-observer variability and the time taken to complete tumour contouring. Nine clinicians contoured the gross tumour volume (GTV) using the PET-CT scans of 10 non-small cell lung cancer (NSCLC) patients, either using DL-assisted or manual contouring tools. After contouring a case using one contouring method, the same case was contoured one week later using the other method. The contours and time taken were compared. Use of the DL-assisted tool led to a statistically significant decrease in active contouring time of 23 % relative to the standard manual segmentation method (p < 0.01). The mean observation time for all clinicians and cases made up nearly 60 % of interaction time for both contouring approaches. On average the time spent contouring per case was reduced from 22 min to 19 min when using the DL-assisted tool. Additionally, the DL-assisted tool reduced contour variability in the parts of tumour where clinicians tended to disagree the most, while the consensus contour was similar whichever of the two contouring approaches was used. A DL-assisted interactive contouring approach decreased active contouring time and local inter-observer variability when used to delineate lung cancer GTVs compared to a standard manual method. Integration of this tool into the clinical workflow could assist clinicians in contouring tasks and improve contouring efficiency.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
To evaluate the impact of a deep learning (DL)-assisted interactive contouring tool on inter-observer variability and the time taken to complete tumour contouring.
MATERIALS AND METHODS METHODS
Nine clinicians contoured the gross tumour volume (GTV) using the PET-CT scans of 10 non-small cell lung cancer (NSCLC) patients, either using DL-assisted or manual contouring tools. After contouring a case using one contouring method, the same case was contoured one week later using the other method. The contours and time taken were compared.
RESULTS RESULTS
Use of the DL-assisted tool led to a statistically significant decrease in active contouring time of 23 % relative to the standard manual segmentation method (p < 0.01). The mean observation time for all clinicians and cases made up nearly 60 % of interaction time for both contouring approaches. On average the time spent contouring per case was reduced from 22 min to 19 min when using the DL-assisted tool. Additionally, the DL-assisted tool reduced contour variability in the parts of tumour where clinicians tended to disagree the most, while the consensus contour was similar whichever of the two contouring approaches was used.
CONCLUSIONS CONCLUSIONS
A DL-assisted interactive contouring approach decreased active contouring time and local inter-observer variability when used to delineate lung cancer GTVs compared to a standard manual method. Integration of this tool into the clinical workflow could assist clinicians in contouring tasks and improve contouring efficiency.

Identifiants

pubmed: 39236985
pii: S0167-8140(24)00770-9
doi: 10.1016/j.radonc.2024.110500
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110500

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Michael J Trimpl (MJ)

Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK; Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK; Mirada Medical Ltd, Oxford, UK. Electronic address: michael.trimpl@wadham.ox.ac.uk.

Sorcha Campbell (S)

Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK. Electronic address: sorcha.campbell@nhslothian.scot.nhs.uk.

Niki Panakis (N)

Oxford University Hospitals NHS Foundation Trust, UK. Electronic address: niki.panakis@ouh.nhs.uk.

Daniel Ajzensztejn (D)

Oxford University Hospitals NHS Foundation Trust, UK. Electronic address: daniel.ajzensztejn@ouh.nhs.uk.

Emma Burke (E)

Oxford University Hospitals NHS Foundation Trust, UK. Electronic address: emma.burke1@ouh.nhs.uk.

Shawn Ellis (S)

Oxford University Hospitals NHS Foundation Trust, UK. Electronic address: shawn.ellis@ouh.nhs.uk.

Philippa Johnstone (P)

Peter MacCallum Cancer Centre, Melbourne, Australia. Electronic address: philippa.johnstone@gmail.com.

Emma Doyle (E)

Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK. Electronic address: emma.doyle@nhs.scot.

Rebecca Towers (R)

Mirada Medical Ltd, Oxford, UK. Electronic address: rebeccajtowers@yahoo.co.uk.

Geoffrey Higgins (G)

Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK. Electronic address: geoffrey.higgins@oncology.ox.ac.uk.

Claire Bernard (C)

Le Centre Hospitalier Universitaire de Liege, BE. Electronic address: c.bernard@chuliege.be.

Roland Hustinx (R)

Le Centre Hospitalier Universitaire de Liege, BE. Electronic address: rhustinx@uliege.be.

Katherine A Vallis (KA)

Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK. Electronic address: katherine.vallis@oncology.ox.ac.uk.

Eleanor P J Stride (EPJ)

Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK. Electronic address: eleanor.stride@eng.ox.ac.uk.

Mark J Gooding (MJ)

Mirada Medical Ltd, Oxford, UK. Electronic address: mark.gooding@inpicturamedica.com.

Classifications MeSH